주식/증권
📉 부정적
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’
요약
Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.